Abstract
Evidence on cardiac remodeling, left ventricular (LV) function recovery, medication use and outcomes in older ST-segment elevation myocardial infarction (STEMI) patients is limited. We examined these aspects at baseline and evolution one year post-infarct in patients aged ≥ 80 versus < 80.STEMI registry data were retrospectively analyzed. The older subgroup included patients aged ≥ 80 years at index hospitalization. Echocardiography was performed at baseline and one year after STEMI. LV remodeling was defined as > 20% relative increase in the LV end-diastolic volume. One-year cardiovascular outcomes and five-year all-cause mortality are reported.Study included 2178 patients; 132 (6.1%) were aged ≥ 80. Older patients had worse baseline LV ejection fraction (47.2 ± 9.6% versus 49.8 ± 8.2%; p < 0.001) and experienced more adverse LV remodeling (29% versus 19%; p = 0.024). Nevertheless, LV function improved similarly in both groups. Beta-blocker and renin-angiotensin-aldosterone system inhibitor use was lower (86.4% versus 94.2%; p < 0.001 and 90.2% versus 96.5%; p < 0.001, respectively) but diuretic prescription higher (18.2% versus 8.1%; p < 0.001) in older patients. One year post-infarct beta-blocker and renin-angiotensin-aldosterone system inhibitor use decreased and was similar in both groups, but older patients continued to receive more diuretics and suffered higher heart failure hospitalization rates (7.0% versus 2.6%; p = 0.006). Five-year mortality was 25.8% in older versus 4.3% in younger patients (log-rank χ2 133.2; p < 0.001).Older patients experienced more adverse LV remodeling, received less beta-blockers and renin-angiotensin-aldosterone system inhibitors but more diuretics at discharge and one year, compared to younger patients. Nevertheless, LV function recovered similarly in both groups.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s10554-026-03775-w.
Keywords: older patients, myocardial infarction, echocardiography, cardiac function, left ventricular remodeling, guideline directed medical therapy
Introduction
With globally increasing longevity, the population ≥ 80 years old is projected to triple from 143 million in 2019 to 426 million in 2050 [1]. Since the incidence of cardiovascular disease increases with age [2], the proportion of older patients having a myocardial infarction (MI) is expected to grow in parallel [3]. Older patients having a MI are characterized by a distinct risk profile [3, 4] and experience high rates of bleeding, heart failure, reinfarction and death [4–6].
Data have consistently shown that older patients have worse left ventricular (LV) systolic and diastolic function after MI [4, 7–9]. However, most previous studies included a high proportion of non-ST-segment elevation MI (NSTEMI) [9] and non-invasive treatment strategies were frequently employed [8, 9]. Detailed information on cardiac function and post-infarct remodeling remains scarce in this age group [8, 10].
Older patients have either been excluded, underrepresented or demonstrated inconclusive results [11–15] in the historical landmark trials that shaped the contemporary treatment of STEMI. Observational data indicate a wide variation in renin-angiotensin system inhibitor, beta-blocker and statin prescriptions on discharge post-MI in this population [7, 8, 16, 17]. Furthermore, few studies have explored how prescription practices change over time [8].
We therefore aimed to evaluate the echocardiographic findings at baseline and one year post-infarct in patients aged ≥ 80 years versus < 80 years, and compare medication prescription practices between these age groups. In addition, we analyzed the prevalence of heart failure hospitalization, MI, new-onset atrial fibrillation, stroke, ventricular tachyarrhythmias, out-of-hospital cardiac arrest and pacemaker implantation.
Methods
Patient population
Patients presenting with STEMI, who were referred for primary percutaneous coronary intervention between 2006 and 2021 at the Leiden University Medical Center (The Netherlands) were included from an ongoing registry (MISSION! ) [18]. All patients were treated according to contemporary European Society of Cardiology guidelines [3]. Clinical, angiographic and survival data from baseline and the pre-planned one year outpatient visit were collected from the hospital information system (EPD-Vision; Leiden University Medical Center, Leiden, The Netherlands), which is linked to municipal registries. Per protocol, comprehensive transthoracic echocardiography was performed within 48 h of the index hospitalization and at the one year outpatient visit post-STEMI. The older patient subgroup included those aged ≥ 80 years at the time of index hospitalization. The study investigated cardiovascular events (heart failure hospitalization, MI, new-onset atrial fibrillation, stroke, ventricular tachyarrhythmias, out-of-hospital cardiac arrest and pacemaker implantation) within the first year, as well as five year all-cause mortality.
All data used in the present study were collected for routine clinical purposes and handled anonymously. For retrospective analysis of clinically acquired data, the institutional review board waived the need for patient written informed consent.
Transthoracic echocardiography
All patients underwent transthoracic echocardiography in the left lateral decubitus position with a commercially available echocardiography system (Vivid 7, Vivid E9, or E95; GE Vingmed Ultrasound, Horten, Norway). Images were acquired and archived for off-line analysis (EchoPac 202, 203 and 204, GE Vingmed Ultrasound, Horten, Norway). LV end-diastolic diameter, LV end-systolic diameter, interventricular septal thickness and LV posterior wall thickness were measured from the parasternal long-axis view. LV mass was calculated by the cube formula from the parasternal long axis view [19] and indexed for body surface area. LV end-diastolic end-systolic volumes were measured and LV ejection fraction (LVEF) was calculated using the biplane Simpson’s method from apical four- and two-chamber views [19]. LV global longitudinal strain (LVGLS) was averaged from apical four-chamber, two-chamber and three-chamber views and measured with two-dimensional speckle tracking. LVGLS values are presented as absolute values. LV remodeling was defined as a relative increase in the LV end-diastolic volume of > 20% one year post-MI [20]. Left atrial volume was measured from apical four- and two-chamber views according to Simpson’s biplane method and indexed for body surface area. LV peak early (E) diastolic velocity was measured using pulsed-wave Doppler traces of transmitral flow. E′ was measured using tissue Doppler imaging at the septal and lateral mitral annulus from the apical four-chamber view and E/E’ calculated. Tricuspid annular plane systolic excursion was measured from the apical four-chamber view. Right ventricular fractional area change was derived from right ventricular end-diastolic and end-systolic areas, obtained from the focused right ventricular apical view. Pulmonary artery systolic pressure was estimated using the peak velocity of the tricuspid regurgitation jet according to the simplified Bernoulli equation, adding the right atrial pressure, estimated by the diameter and inspiratory collapse of the inferior vena cava. Valvular dysfunction was evaluated according to the current recommendations [21] and the severity reported as a categorical variable.
Statistical analysis
Continuous data are presented as mean ± standard deviation or median and interquartile range, as appropriate. Categorical data are presented as frequencies and percentages. Continuous variables were compared with independent samples t-tests if normally distributed or Mann-Whitney U tests if non-normally distributed. Categorical variables were compared with chi-square tests or the Fisher exact test. Changes in echocardiographic parameters over time within the groups were compared using the paired t-test for continuous variables and the McNemar test for categorical variables. Changes over time between the groups were compared using linear mixed models for continuous variables and general linear mixed models for categorical variables. Survival differences between the groups were demonstrated by Kaplan-Meier curves and compared using the log-rank test. Statistical analysis was performed using SPSS version 29.0 (IBM, Armonk, New York, USA). All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant.
Results
The study population included 2178 patients (mean age 61 ± 12 years; 75% male). Baseline characteristics are shown in Table 1. A total of 132 patients (6.1%) were aged ≥ 80 years. This group included a higher proportion of women, had more comorbidities, worse kidney function, lower diastolic blood pressure, a higher heart rate and a trend towards higher troponin levels on admission when compared to younger patients, who had a slightly higher body mass index and four-times higher prevalence of smoking.
Table 1.
Baseline clinical characteristics of the study population, stratified according to the age groups
| Parameter | Overall population (N = 2178) |
≥ 80-year-olds (N = 132) |
< 80-year-olds (N = 2046) |
p value |
|---|---|---|---|---|
| Age, years | 60.9 ± 11.7 | 83.1 ± 2.9 | 59.5 ± 10.5 | < 0.001 |
| Male | 1638 (75.2%) | 78 (59.1%) | 1560 (76.2%) | < 0.001 |
| Arterial hypertension | 839 (38.6%) | 77 (59.2%) | 762 (37.3%) | < 0.001 |
| Hyperlipidemia | 504 (23.2%) | 31 (23.7%) | 473 (23.2%) | 0.90 |
| Previous MI | 131 (6%) | 12 (9.1%) | 119 (5.8%) | 0.13 |
| History of CHF | 25 (1.1%) | 4 (3.0%) | 21 (1%) | 0.036 |
| Previous AF | 47 (2.2%) | 9 (6.8%) | 38 (1.9%) | < 0.001 |
| Family history of CAD | 937 (43.5%) | 20 (15.4%) | 917 (45.3%) | < 0.001 |
| Diabetes mellitus | 234 (10.8%) | 22 (16.7%) | 212 (10.4%) | 0.024 |
| Prior statin use | 382 (17.6%) | 28 (21.7%) | 354 (17.4%) | 0.21 |
| Current smoker | 862 (39.6%) | 14 (10.6%) | 848 (41.4%) | < 0.001 |
| COPD | 84 (3.9%) | 11 (8.3%) | 73 (3.6%) | 0.006 |
| BMI, kg/m2 | 26.8 ± 4.1 | 26.1 ± 4.1 | 26.9 ± 4 | 0.022 |
| Peak troponin T, ng/l | 3080 (1230; 6320) | 3747 (1790; 7935) | 2990 (1198; 6240) | 0.09 |
| eGFR (CKD-EPI 2021), ml/min/1.73m2 | 93 (78; 102) | 69 (54; 80) | 94 (80; 103) | < 0.001 |
| LM/LAD as culprit | 974 (44.7%) | 64 (48.5%) | 910 (44.5%) | 0.37 |
| Number of vessels diseased | < 0.001 | |||
| One | 939 (43.1%) | 31 (23.5%) | 908 (44.4%) | |
| Two | 724 (33.2%) | 46 (34.8%) | 678 (33.1%) | |
| Three | 515 (23.6%) | 55 (41.7%) | 460 (22.5%) | |
| Multivessel disease | 1239 (56.9%) | 101 (76.5%) | 1138 (55.6%) | < 0.001 |
| Systolic blood pressure on admission, mmHg | 135 ± 25 | 137 ± 28 | 135 ± 25 | 0.25 |
| Diastolic blood pressure on admission, mmHg | 81 ± 16 | 77 ± 16 | 82 ± 16 | < 0.001 |
| Heart rate at discharge, bpm | 69 ± 12 | 72 ± 13 | 69 ± 12 | 0.002 |
| QRS > 120 ms | 135 (6.2%) | 25 (18.9%) | 110 (5.4%) | < 0.001 |
| LBBB present | 24 (1.1%) | 6 (4.5%) | 18 (0.9%) | < 0.001 |
Data are presented as mean ± standard deviation, median (interquartile range) and n (%). Abbreviations: AF: atrial fibrillation; BMI: body mass index; bpm: beats per minute; CAD: coronary artery disease; CHF: chronic heart failure; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LAD: left anterior descending artery; LBBB: left bundle branch block; LM: left main stem; MI: myocardial infarction
Baseline echocardiographic findings
The baseline echocardiographic results are summarized in Table 2. Older patients had smaller LV end-diastolic dimension, greater LV mass and worse LV systolic function, with lower LVEF and LVGLS. Furthermore, higher LV filling pressures, greater left atrial volumes, increased pulmonary artery systolic pressures and worse right ventricular systolic function (measured by tricuspid annular plane systolic excursion) were noted in older patients. Severe valvular pathology was infrequent in the study population. Altogether, 19 (0.9%) patients had severe mitral regurgitation, 12 (0.6%) severe tricuspid regurgitation and two patients in each group had severe aortic stenosis.
Table 2.
Baseline and one year-follow-up echocardiographic characteristics, stratified according to the age groups
| Parameter | Overall population (N = 2178) baseline |
Overall population (N = 1980) follow-up |
≥ 80-year-olds (N = 132) baseline |
≥ 80-year-olds (N = 86) follow-up |
p value | < 80-year-olds (N = 2046) follow-up |
< 80-year-olds (N = 1894) follow-up |
p value | p value for baseline measurements | p value for change between groups |
|---|---|---|---|---|---|---|---|---|---|---|
| LVEDD, mm | 49 ± 5.5 | 50 ± 5.7 | 47 ± 6 | 49 ± 6.2 | 0.15 | 49 ± 5.4 | 50 ± 5.7 | < 0.001 | < 0.001 | 0.77 |
| LVESD, mm | 32 ± 6.4 | 32 ± 7.2 | 31 ± 6.9 | 32 ± 7.4 | 0.25 | 32 ± 6.4 | 32 ± 7.2 | 0.1 | 0.25 | 0.3 |
| IVST, mm | 11.3 ± 1.6 | 10.8 ± 1.5 | 11.9 ± 1.5 | 11.6 ± 1.6 | 0.4 | 11.2 ± 1.6 | 10.8 ± 1.5 | < 0.001 | < 0.001 | 0.17 |
| PWT, mm | 9.9 ± 1.4 | 9.5 ± 1.3 | 10 ± 1.5 | 9.5 ± 1.3 | 0.027 | 9.9 ± 1.4 | 9.5 ± 1.3 | < 0.001 | 0.41 | 0.99 |
| LVEDV, ml | 136 ± 45 | 141 ± 48 | 122 ± 47 | 132 ± 44 | 0.001 | 137 ± 45 | 142 ± 48 | < 0.001 | < 0.001 | 0.064 |
| LV remodeling, % | 388 (19.6%) | 25 (29.1%) | 363 (19.2%) | 0.024* | ||||||
| LVEDVI, ml/ m2 | 68 ± 21 | 71 ± 22 | 65 ± 23 | 71 ± 22 | < 0.001 | 69 ± 21 | 71 ± 22 | < 0.001 | 0.10 | 0.039 |
| LVESV, ml | 69 ± 29 | 68 ± 31 | 65 ± 34 | 66 ± 31 | 0.35 | 70 ± 29 | 68 ± 31 | < 0.001 | 0.11 | 0.079 |
| LVESVI, ml/ m2 | 35 ± 14 | 34 ± 15 | 35 ± 17 | 35 ± 16 | 0.33 | 35 ± 14 | 34 ± 15 | < 0.001 | 0.96 | 0.052 |
| LVMI, ml/ m2 | 97 ± 21 | 94 ± 21 | 101 ± 22 | 102 ± 26 | 0.9 | 96 ± 21 | 94 ± 21 | < 0.001 | 0.013 | 0.15 |
| LVEF, % | 49.7 ± 8.3 | 53.2 ± 7.9 | 47.2 ± 9.6 | 51.9 ± 9.2 | < 0.001 | 49.8 ± 8.2 | 53 ± 7.9 | < 0.001 | < 0.001 | 0.77 |
| LVEF < 40% | 279 (12.8%) | 121 (6.1%) | 28 (21.5%) | 8 (9.3%) | 0.033 | 251 (12.3%) | 113 (6.0%) | < 0.001 | 0.002 | 0.85 |
| LVGLS, % | 13.9 ± 3.6 | 16 ± 3.4 | 12.9 ± 4 | 15.1 ± 3.8 | < 0.001 | 14.0 ± 3.6 | 16 ± 3.3 | < 0.001 | 0.001 | 0.3 |
| LVGLS < 16.0% | 1477 (69.0%) | 869 (44.6%) | 96 (76.8) | 47 (55.3%) | < 0.001 | 1381 (68.5%) | 822 (44.1) | < 0.001 | 0.053 | 0.41 |
| E/E’ | 10.9 ± 4.2 | 9.5 ± 4.2 | 13.8 ± 5.3 | 11.8 ± 5.0 | 0.004 | 10.7 ± 4.1 | 9.4 ± 4.2 | < 0.001 | < 0.001 | 0.02 |
| E/A | 0.99 ± 0.42 | 0.97 ± 0.42 | 0.81 ± 0.48 | 0.75 ± 0.4 | 0.87 | 1 ± 0.41 | 0.98 ± 0.41 | 0.07 | < 0.001 | 0.62 |
| LAVI, ml/ m2 | 28.3 ± 9.8 | 30.6 ± 10.3 | 32.5 ± 14 | 36.5 ± 14.2 | < 0.001 | 28.1 ± 9.5 | 30.4 ± 10 | < 0.001 | < 0.001 | < 0.001 |
| PASP, mm Hg | 26 ± 10 | 24.5 ± 9.3 | 30 ± 11 | 31.6 ± 13.2 | 0.54 | 26 ± 10 | 24.2 ± 8.9 | 0.39 | < 0.001 | 0.1 |
| RVEDA, cm2 | 22.1 ± 6.2 | 23.6 ± 6.5 | 20.8 ± 5.8 | 21.8 ± 6.2 | 0.042 | 22.2 ± 6.2 | 23.7 ± 6.5 | < 0.001 | 0.013 | 0.48 |
| RVESA, cm2 | 12.7 ± 4.3 | 13.2 ± 4.3 | 12.3 ± 4.4 | 12.7 ± 4.5 | 0.062 | 12.7 ± 4.3 | 13.2 ± 4.3 | < 0.001 | 0.25 | 0.71 |
| RVFAC, % | 43 ± 8.4 | 44 ± 7.9 | 42 ± 8.2 | 43 ± 7 | 0.9 | 43 ± 8.4 | 44 ± 8 | < 0.001 | 0.51 | 0.36 |
| TAPSE, mm | 20 ± 3.1 | 20.6 ± 3.2 | 19.2 ± 3.4 | 19.6 ± 2.5 | 0.53 | 20 ± 3.1 | 21 ± 3.2 | 0.002 | 0.006 | 0.31 |
| Severe MR | 19 (0.9%) | 21 (1.1%) | 2 (1.5%) | 1 (1.2%) | > 0.99 | 17 (0.9%) | 20 (1.1%) | 0.18 | 0.42 | 0.50 |
| Severe TR | 12 (0.6%) | 10 (0.5%) | 3 (2.3%) | 1 (1.2%) | 0.56 | 9 (0.4%) | 9 (0.5%) | 0.59 | 0.006 | 0.38 |
Data are presented as mean ± standard deviation and n (%). * p value for comparison between the groups on follow-up.Abbreviations: IVST: interventricular septal thickness; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEDVI: left ventricular end-diastolic volume index; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-systolic volume; LVESVI: left ventricular end-systolic volume index; LVGLS: left ventricular global longitudinal strain; LVMI: left ventricular mass index; MR: mitral regurgitation; PASP: pulmonary artery systolic pressure; PWT: posterior wall thickness; RVEDA: right ventricular end-diastolic area; RVESA: right ventricular end-systolic area; RVFAC: right ventricular fractional area change; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation
Discharge medication and follow-up
Discharge medication is summarized in Fig. 1. Anticoagulation was prescribed more frequently in older patients, while the use of triple antithrombotic therapy was similar between the two groups. Older patients received less anti-remodeling pharmacotherapy, namely renin-angiotensin-aldosterone system inhibitors and beta-blockers, but were prescribed more aldosterone antagonists, calcium channel antagonists and diuretics.
Fig. 1.

Medication at hospital discharge and at one year stratified according to the age groups Abbreviations: RAASI: renin-angiotensin-aldosterone system inhibitors. *p < 0.05 for change within the group
198 (9.1%) patients did not undergo a follow-up echocardiogram, which was more commonly encountered in older versus younger patients (35% versus 7.4%, χ2 112.8; p < 0.001).
Patients aged ≥ 80 years who were lost to follow-up were older, had higher rates of atrial fibrillation and a trend towards lower LVEF when compared to the subgroup who did undergo follow-up echocardiography (Supplemental Table 1).
Evolution of cardiac function and dimensions at one year post-STEMI
One year follow-up echocardiography was available in 1980 (91%) patients (Table 2). Older patients experienced higher rates of adverse LV remodeling, compared to younger individuals. Nonetheless, both groups demonstrated a similar improvement in LVEF and LVGLS at follow-up. At one year, the percentage of patients with LVEF below 40% was similar between the two groups (p = 0.21), although LVGLS below 16% was more common in the older patients (p = 0.04).
LV filling pressure improved to a greater extent in older patients, but the increase in left atrial volume index was also more pronounced in this group.
Medication prescription changes at one year
At one year follow-up, a decrease in the prescription of antiplatelet agents, renin-angiotensin-aldosterone system inhibitors, beta-blockers and statins was observed in both groups (Fig. 1). The younger patient group received more often aspirin, while older patients received more often anticoagulants, diuretics and nitrates.
Outcomes
During the first year after STEMI, older patients experienced higher rates of heart failure hospitalization, new-onset atrial fibrillation, pacemaker implantation and a trend towards more strokes, in comparison to younger patients (Table 3). During a median follow-up of 60 (47; 60) months, 122 patients died. One- and five-year mortality was 14 (10.6%) and 34 (25.8%) in older patients versus 24 (1.2%) and 88 (4.3%) in younger patients (log-rank χ2 133.2; p < 0.001; Fig. 2).
Table 3.
One year outcomes stratified according to the age groups
| Character | Overall population (N = 2178) |
≥ 80-year-olds (N = 132) |
< 80-year-olds (N = 2046) |
p value |
|---|---|---|---|---|
| All-cause mortality | 38 (1.7%) | 14 (10.6%) | 24 (1.2%) | < 0.001 |
| Heart failure hospitalization | 60 (2.9%) | 8 (7.0%) | 52 (2.6%) | 0.006 |
|
Recurrent myocardial infarction |
43 (2.1%) | 1 (0.9%) | 42 (2.1%) | 0.36 |
| New-onset atrial fibrillation | 136 (6.5%) | 17 (14.9%) | 119 (6.0%) | < 0.001 |
| Stroke | 0.059 | |||
| Ischemic stroke | 18 (0.9%) | 2 (1.8%) | 16 (0.8%) | |
| Hemorrhagic stroke | 3 (0.1%) | 1 (0.9%) | 2 (0.1%) | |
| Ventricular tachyarrhythmias | 26 (1.2%) | 2 (1.8%) | 24 (1.2%) | 0.61 |
| Out-of-hospital cardiac arrest | 5 (0.2%) | 0 | 5 (0.2%) | 0.76 |
| Pacemaker implantation | 10 (0.5%) | 3 (2.6%) | 7 (0.4%) | < 0.001 |
Data are presented as n (%)
Fig. 2.

Kaplan-Meier curve for five-year all-cause mortality, stratified according to the age groups
Discussion
The present study explored echocardiographic characteristics, cardiac remodeling and medication prescription practices in older patients. The main findings can be summarized as follows: (1) while patients aged ≥ 80 had worse left and right ventricular function at the index hospitalization, suffered more LV remodeling and a greater increase in left atrial volume, they demonstrated a similar improvement in LV systolic function, compared to younger patients (< 80 years), (2) older patients were prescribed less beta-blockers and renin-angiotensin-aldosterone system inhibitors at discharge but received more diuretics, (3) while at one year post-MI the prescription rates of anti-remodeling pharmacotherapy (beta-blockers and renin-angiotensin aldosterone inhibitors) were similar in both groups, older patients continued to receive more symptom-targeted medication and suffered higher rates of heart failure hospitalizations and (4) although the five-year all-cause mortality was six times higher in the older patient group, the overall survival rates remained relatively good, considering the high risk profile of these patients.
Cardiac function in older MI patients
Older patients more frequently present with atypical complaints, tend to wait longer before seeking medical attention [3] and have more extensive LV damage from myocardial infarctions [4, 7–9]. Nevertheless, published data on cardiac recovery and remodeling in older patients remain limited. Ennezat et al. reported similar rates of LV remodeling across age groups after acute anterior MI [8]. Importantly, this study excluded patients aged > 85 years and less than a third received primary percutaneous coronary intervention [8]. In contrast, Carrabba et al. demonstrated less improvement of LVEF and more adverse remodeling six months after STEMI in patients aged > 70 years who were treated by primary percutaneous coronary intervention [10]. We expand on these findings with data from a large, contemporary STEMI registry, showing an increased incidence of adverse LV remodeling, but a similar improvement of LV systolic function, in those ≥ 80 years of age.
Adverse LV remodeling in older patients may be explained by age-related changes in myocardial structure. First, the total number of cardiomyocytes decreases, along with hypertrophy in the remaining ones. Second, an increase in extracellular matrix volume and alterations in its composition, mediate fibrosis and subsequent remodeling [22, 23]. A study analyzing scar formation after MI in senescent mice observed a marked decrease in collagen deposition, with a reduced tensile strength of myocardial scar likely predisposing patients to increased LV dilation (adverse remodeling) [22]. These findings indicate that increased myocardial vulnerability with aging may manifest as greater susceptibility to adverse remodeling while preserving the ability to recover LV systolic function.
The larger increase in left atrial volume index we observed in older patients, might be ascribed to differing tissue characteristics, but not to worsening LV filling pressures, since greater improvement in LV filling pressures was noted in the older patient group. Importantly though, higher rates of new-onset atrial fibrillation during the first year after MI and increased use of anticoagulation were noted, suggesting that atrial fibrillation-related left atrial remodeling is the more likely mechanism of adverse left atrial remodeling. Given the high bleeding risk associated with anticoagulant use in older adults, our findings further support the need to implement strategies to reduce atrial remodeling.
Anti-remodeling therapy in older patients
Both beta-blockers and renin-angiotensin-aldosterone system inhibitors have demonstrated effectiveness in ameliorating adverse, post-infarct remodeling [24, 25]. However, since older individuals have been excluded or underrepresented in most landmark trials [3], current guidelines recommend caution to extrapolate these conclusions to the elderly [3]. Physicians often hesitate to escalate treatment or discontinue current medications in older patients, not only due to the limited evidence base, but also because of concerns about polypharmacy and adverse effects [26]. While optimal medical therapy implementation after STEMI can be more complex due to transient LV dilation and dysfunction, simultaneous start of several blood pressure-lowering medications and intensive diuretic therapy resulting in negative fluid balance and hypotension [27]. In this setting, echocardiography, including quantitative Doppler data, might be useful in guiding therapy adjustment [27]. Older patients in our study presented with worse renal function and lower diastolic blood pressure. Both observations are relevant when deciding to start anti-remodeling therapy as they may indicate potential hemodynamic tolerance issues. Ennezat et al. showed similar use of beta-blockers and renin-angiotensin-aldosterone system inhibitors upon discharge across different age groups after MI, yet on follow-up older patients were prescribed beta-blockers less frequently [8]. In contrast, Perl et al. and Yudi et al. reported lower prescription rates of renin-angiotensin-aldosterone system inhibitors or angiotensin-converting-enzyme inhibitors, but no differences in beta-blocker use [16, 17]. We observed significantly lower prescription rates of beta-blockers and renin-angiotensin-aldosterone system inhibitors at discharge in older patients, with further decreasing use in both age groups (≥/< 80 years) at one-year follow-up. Nevertheless, in our population, prescription rates of these medications in older patients remained comparable to or higher than previously reported, with 80.7% and 86.7% receiving beta-blockers and renin-angiotensin-aldosterone system inhibitors at one year, respectively.
Outcomes and clinical implications
Current guidelines advise against using advanced age as a reason to withhold primary percutaneous coronary intervention in STEMI [3]. Other than that, most questions about treatment strategies of older patients have not been tested in trials, and decision-making remains in the hands of treating physician [28]. All patients in our study received primary percutaneous coronary intervention, which might explain the relatively high survival rates [4, 5]. Nevertheless, older patients experienced six times higher five-year mortality rates, likely due to several contributing factors. First, increasing age is independently associated with all-cause mortality [3, 29]. Second, older patients tend to have a higher burden of cardiac and non-cardiac comorbidities (which was also observed in our cohort, and included pacemaker implantation and new-onset atrial fibrillation) [6]. Third, lower baseline LVEF post-infarct remains a well-established risk factor for adverse events [3]. Of note, while adverse LV remodeling is not independently associated with mortality, we have previously shown that it is associated with higher rates of heart failure hospitalization [30]. Consistent with these findings, our study showed that older patients suffered more heart failure hospitalizations and were prescribed more diuretics and nitrates over time.
The high rates of new-onset atrial fibrillation and pacemaker implantation suggest that more frequent electrocardiographic surveillance may be appropriate in older patients. Medication prescription rates at discharge and one year indicate a focus on symptomatic, rather than disease-modifying care. Heart failure hospitalization was higher in the older group, which might have been reduced by more aggressive anti-remodeling pharmacotherapy. A relatively high loss to follow-up echocardiography was observed in the older group (35% versus 7.4% younger patients), which cannot be entirely accounted for by mortality (10.6% at one year in the older patient group). Rather it likely reflects practical barriers to attending appointments such as needing transportation or assistance, and more frequent preference for palliative care over active treatment in this population. Targeted, randomized trials to guide treatment decisions in older patients are required and should incorporate outcomes such as quality of life and functional status.
Study limitations
The main limitations of this study are related to its single-center, retrospective design and a relatively low number of older patients. Data on frailty and the exact cause of death were not systematically available and are therefore not reported. Granular details on the indication for permanent pacemaker implantation were not recorded in the database from which the analysis was performed. Since the study included patients presenting with STEMI from 2005 to 2021, the use of sodium-glucose cotransporter 2 inhibitors, angiotensin receptor-neprilysin inhibitors and proprotein convertase subtilisin/kexin type 9 inhibitors was not reported. More patients from the older group were lost to follow-up – subsequently, follow-up echocardiography findings likely represent the more active, older patient group and cannot be extrapolated to all older patients, including extremely frail ones.
Conclusions
STEMI patients ≥ 80 years of age experienced more adverse LV remodeling and higher rates of cardiovascular events like heart failure hospitalization as compared to younger patients yet received less anti-remodeling medication and more symptom-focused treatment. Despite this apparent handicap, older patients (≥ 80 years) demonstrated comparable cardiac function recovery to younger patients and better survival than previously been reported.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
All individuals who have substantially contributed to the manuscript, have been included as authors.
Abbreviations
- LV
left ventricle
- LVEF
left ventricular ejection fraction
- LVGLS
left ventricular global longitudinal strain
- MI
myocardial infarction
- STEMI
ST-segment elevation myocardial infarction
Author contributions
LC, RM, XG, DL, TN, NAM, JJB and PvdB contributed to the study concept and methodology. LC, RM, XG, DL, JS, TN, IY, MCM, JHK, IJvdH, SEvR, HWW, VMvdB and AG contributed to the acquisition, analysis, and interpretation of data. LC wrote the original draft. RM, XG, DL, JS, TN, IY, MCM, JHK, IJvdH, SEvR, HWW, VMvdB, AG, KT, NAM, JJB and PvdB reviewed and edited the manuscript. LC performed the statistical analysis. LC, RM, XG, DL, JS, TN, IY, MCM, JHK, IJvdH, SEvR, HWW, VMvdB, NAM, JJB and PvdB accessed and verified data. NAM and JJB obtained funding. NAM, JJB and PvdB provided administrative, technical, and material support. KT, NAM, JJB and PvdB provided supervision. All authors take responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all the data in the study and final responsibility for the decision to submit for publication.
Funding
This study is supported by a Novartis AG research grant.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Declarations
Competing interests
This study is supported by a Novartis AG research grant. The Department of Cardiology of the Leiden University Medical Center received research grants from Abbott Vascular, Alnylam, Bayer, Biotronik, Bioventrix, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic, Pie Medical, Medis, Pfizer and Novartis. Jeroen J Bax received speaker fees from Abbott Vascular, Edwards Lifesciences and Omron. Nina Ajmone Marsan received speaker fees from Abbott Vascular, Philips Ultrasound, Omron, GE Healthcare and Pfizer. Karlis Trusinskis received speaker fees from Abbvie, Astra Zeneca, Bayer, Berlin Menarini, Boehringer-Ingelheim, Biotronik, Medtronic, Novo-Nordisk, Pfizer and Servier. Pieter van der Bijl received speaker fees from GE Healthcare. All other authors have no relationships relevant to the contents of this paper to disclose.
Ethics approval
All data used in the current analysis were collected for routine clinical purposes and handled anonymously. The requirement for written informed consent was waived by the institutional review board on a patient level due to the retrospective design of the study.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.United Nations DoEaSA, Population Division (2020) World Population Ageing 2019. ST/ESA/SER..A/444
- 2.Shirakabe A, Ikeda Y, Sciarretta S, Zablocki DK, Sadoshima J (2016) Aging and Autophagy in the Heart. Circ Res 118(10):1563–1576 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 44(38):3720–3826 [DOI] [PubMed] [Google Scholar]
- 4.Bromage DI, Jones DA, Rathod KS, Grout C, Iqbal MB, Lim P et al (2016) Outcome of 1051 Octogenarian Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group. J Am Heart Assoc. ;5(6) [DOI] [PMC free article] [PubMed]
- 5.Claessen BE, Kikkert WJ, Engstrom AE, Hoebers LP, Damman P, Vis MM et al (2010) Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart 96(11):843–847 [DOI] [PubMed] [Google Scholar]
- 6.Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G et al (2005) Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149(1):67–73 [DOI] [PubMed] [Google Scholar]
- 7.Sappa R, Grillo MT, Cinquetti M, Prati G, Spedicato L, Nucifora G et al (2017) Short and long-term outcome in very old patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Int J Cardiol 249:112–118 [DOI] [PubMed] [Google Scholar]
- 8.Ennezat PV, Lamblin N, Mouquet F, Tricot O, Quandalle P, Aumegeat V et al (2008) The effect of ageing on cardiac remodelling and hospitalization for heart failure after an inaugural anterior myocardial infarction. Eur Heart J 29(16):1992–1999 [DOI] [PubMed] [Google Scholar]
- 9.Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM (2003) Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 114(4):307–315 [DOI] [PubMed] [Google Scholar]
- 10.Carrabba N, Parodi G, Valenti R, Migliorini A, Antoniucci D (2009) Comparison of effects of primary coronary angioplasty on left ventricular remodeling and heart failure in patients < 70 versus > or = 70 years with acute myocardial infarction. Am J Cardiol 104(7):926–931 [DOI] [PubMed] [Google Scholar]
- 11.Randomised trial of cholesterol lowering (1994) in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389 [PubMed] [Google Scholar]
- 12.Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G et al (1981) Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2(8251):823–827 [DOI] [PubMed] [Google Scholar]
- 13.Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669–677 [DOI] [PubMed] [Google Scholar]
- 14.Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG et al (2016) Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 353:i1855 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504 [DOI] [PubMed] [Google Scholar]
- 16.Yudi MB, Hamilton G, Farouque O, Andrianopoulos N, Duffy SJ, Lefkovits J et al (2017) Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged < 75, 75 to 84, and >/=85 Years With ST-Elevation Myocardial Infarction. Am J Cardiol 120(8):1245–1253 [DOI] [PubMed] [Google Scholar]
- 17.Perl L, Franze A, D’Ascenzo F, Golomb N, Levi A, Vaknin-Assa H et al (2021) Elderly Suffering from ST-Segment Elevation Myocardial Infarction-Results from a Database Analysis from Two Mediterranean Medical Centers. J Clin Med. ;10(11) [DOI] [PMC free article] [PubMed]
- 18.Liem S-S, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J et al (2007) MISSION! Optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 153(1):14.e1-.e1 [DOI] [PubMed] [Google Scholar]
- 19.Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270 [DOI] [PubMed] [Google Scholar]
- 20.Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106(18):2351–2357 [DOI] [PubMed] [Google Scholar]
- 21.Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA et al (2017) Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30(4):303–371 [DOI] [PubMed] [Google Scholar]
- 22.Chen W, Frangogiannis NG (2010) The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 15(5):415–422 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Tracy E, Rowe G, LeBlanc AJ (2020) Cardiac tissue remodeling in healthy aging: the road to pathology. Am J Physiol Cell Physiol 319(1):C166–C82 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N et al (2004) Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 109(2):201–206 [DOI] [PubMed] [Google Scholar]
- 25.St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR et al (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89(1):68–75 [DOI] [PubMed] [Google Scholar]
- 26.Davies EA, O’Mahony MS (2015) Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol 80(4):796–807 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Lei J, Chong TK, Gao J, Chen J, Liu K (2026) The roles of quantitative doppler echocardiography in optimizing guideline-directed medical therapy in Post-STEMI patients. Int J Cardiovasc Imaging [DOI] [PMC free article] [PubMed]
- 28.Pavasini R, Biscaglia S, Kunadian V, Hakeem A, Campo G (2024) Coronary artery disease management in older adults: revascularization and exercise training. Eur Heart J 45(31):2811–2823 [DOI] [PubMed] [Google Scholar]
- 29.Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W et al (1989) The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 117(3):543–549 [DOI] [PubMed] [Google Scholar]
- 30.van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR Jr., Marsan A (2020) Left Ventricular Post-Infarct Remodeling: Implications for Systolic Function Improvement and Outcomes in the Modern Era. JACC Heart Fail 8(2):131–140 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
